We Think You Should Be Aware Of Some Concerning Factors In Carysil's (NSE:CARYSIL) Earnings

Following the solid earnings report from Carysil Limited (NSE:CARYSIL), the market responded by bidding up the stock price. While the profit numbers were good, our analysis has found some concerning factors that shareholders should be aware of.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

One essential aspect of assessing earnings quality is to look at how much a company is diluting shareholders. Carysil expanded the number of shares on issue by 6.1% over the last year. That means its earnings are split among a greater number of shares. To celebrate net income while ignoring dilution is like rejoicing because you have a single slice of a larger pizza, but ignoring the fact that the pizza is now cut into many more slices. You can see a chart of Carysil's EPS by clicking here.

A Look At The Impact Of Carysil's Dilution On Its Earnings Per Share (EPS)

You can see above that Carysil's profit is about the same as it was three years back. In contrast, its earnings per share is down 6.2% per year over the same period. The fact that profit was up 10% last year gives a good impression. On the other hand, earnings per share are only up 5.4% in the same time frame. So you can see that the dilution has had a bit of an impact on shareholders.

Changes in the share price do tend to reflect changes in earnings per share, in the long run. So it will certainly be a positive for shareholders if Carysil can grow EPS persistently. However, if its profit increases while its earnings per share stay flat (or even fall) then shareholders might not see much benefit. For the ordinary retail shareholder, EPS is a great measure to check your hypothetical "share" of the company's profit.

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

Our Take On Carysil's Profit Performance

Each Carysil share now gets a meaningfully smaller slice of its overall profit, due to dilution of existing shareholders. Therefore, it seems possible to us that Carysil's true underlying earnings power is actually less than its statutory profit. But at least holders can take some solace from the 5.4% EPS growth in the last year. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. If you'd like to know more about Carysil as a business, it's important to be aware of any risks it's facing. To that end, you should learn about the 2 warning signs we've spotted with Carysil (including 1 which makes us a bit uncomfortable).

This note has only looked at a single factor that sheds light on the nature of Carysil's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.